HepaRegeniX
heparegenix.com
Actively hiring
Financial Services
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$39.4M
2 rounds on record
Latest round
$23.2M
Venture round · Apr 2025 · 17 mo ago
Backers
1
Coparion
The money's age
Due for its next round
17 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 15, 2025
Raised a round Venture round $23.2M · YahooFinance
Oct 22, 2024
Board appointment HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board · heparegenix.com
Jul 10, 2024
Raised a round Series C $16.2M
2016
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2025 | $23.2M | — | YahooFinance |
| Series C | Jul 2024 | $16.2M | — | heparegenix.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Coparion Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Early detection of cancer, liver disease and over 500 other diseases. Receive a personal health action plan with full body MRI and blood…
Sequana Medical is a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer.
Ochre Bio is a London biotechnology company founded in 2019 that develops RNA medicines for chronic liver disease. It tests candidates on…
Heart & Soil offers a wide range of nutrient-rich desiccated organ supplements, liver supplements, and everything you need for optimal…
Invest on Wefunder ABOUT HEPATX STRATEGY TEAM CAREERS SCIENCE MEDIA CONTACT US Optimal Go-to-Market Strategy We are on a mission to…
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
News
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
HepaRegeniX to seamlessly advance darizmetinib's clinical development to Phase 2a following completion of the Phase 1b in 2026Tuebingen, Germany, ...
Read more
Report
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
HepaRegeniX to seamlessly advance darizmetinib's clinical development to Phase 2a following completion of the Phase 1b in 2026 Tuebingen, Germany, September 22, 2026 - HepaRegeniX GmbH ("HepaRegeniX"), a clinical-stage biotech company advancing novel ther
Read more
Report
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
Read more
Report
HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure
U.S. FDA Orphan Drug Designation underscores darizmetinib's potential to address a significant unmet need following liver resection Tuebingen, Ger...
Read more
Report
HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure
U.S. FDA Orphan Drug Designation underscores darizmetinib's potential to address a significant unmet need following liver resection Tuebingen, Germany, August 26, 2026 - HepaRegeniX GmbH ("HepaRegeniX"), a clinical-stage biotech company advancing novel th
Read more
Report
HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure
U.S. FDA Orphan Drug Designation underscores darizmetinib's potential to address a significant unmet need following liver resection
Read more
Report
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
Tuebingen, Germany, May 13, 2026 - HepaRegeniX GmbH ("HepaRegeniX"), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical data for the lead candidate darizmetini
Read more
Report
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
Tuebingen, Germany, May 13, 2026 - HepaRegeniX GmbH (
Read more
Report
HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection
Tuebingen, Germany, February 11, 2026 - HepaRegeniX GmbH ("HepaRegeniX"), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib minor resection study of HRX-215. Fiv
Read more
Report
HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration
Tuebingen, Germany, June 10, 2025 - HepaRegeniX GmbH ("HepaRegeniX"), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of it
Read more
Report
Show more news